• Mashup Score: 3
    Home - 4 day(s) ago

    Thursday, 12 June 2025 08:00 – 09:30 CEST Allianz MiCo – Milano Convention Centre | 20149 Milan, Italy Room: Brown Hall 3 CPD Hybrid Multiple myeloma (MM) remains a challenging hematologic malignancy, with most patients experiencing relapse despite initial treatment success. The management of relapsed/refractory MM (R/R MM) has evolved significantly with the advent of novel therapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and chimeric antigen receptor (CAR)

    Tweet Tweets with this article
    • 🧬 Understand how prognosis evolves through relapse cycles in MM. Gain confidence in SDM, 💊personalize treatment, and 🤝 improve communication in R/R MM care. 🔗 https://t.co/C7tcZh6Xc4 Moderated by: @jmikhaelmd https://t.co/Y6TD5omzkZ